Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

How to ride the second Chinese biosimilar wave

This article was originally published in Scrip

Executive Summary

Today, 40% of China’s recombinant biologic product sales come from biosimilars, which have enjoyed a 25-30% compound annual growth rate (CAGR) over the past 10 years, led by a group of domestic products. What should multinational companies consider when evaluating the biosimilar market in China, and what is the best entry strategy?



Related Companies